Shares of Allergy Therapeutics plc (LON:AGY – Get Free Report) hit a new 52-week low during mid-day trading on Wednesday. The company traded as low as GBX 3.97 and last traded at GBX 4.20, with a volume of 523,405 shares. The stock had previously closed at GBX 4.25.
Allergy Therapeutics Trading Down 1.2%
The company has a current ratio of 1.13, a quick ratio of 1.48 and a debt-to-equity ratio of 629.58. The stock has a market capitalization of £265.97 million, a price-to-earnings ratio of -4.33, a PEG ratio of -30.70 and a beta of 0.83. The firm has a 50-day moving average of GBX 4.98 and a 200 day moving average of GBX 8.22.
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
Featured Articles
- Five stocks we like better than Allergy Therapeutics
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
- Amkor’s Mobile Business Is Slowing, But Its AI Ambitions Aren’t
- Want to Own a Piece of Professional Sports? This ETF Could Be Your Ticket
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
